GENESIS

Award-Winning AI-Artist Sougwen Chung debuts at K11 MUSEA, Hong Kong

Retrieved on: 
Tuesday, March 19, 2024
GENESIS, Culture, VR, Science, MIT Media Lab, Victoria Dockside, AI, Fear, Hope, Nature, Exhibition, K11, TIME100 Impact Awards, Creativity, Commerce, Data, Collection, Movement, Soho House, Virtual reality

Sougwen Chung, a Chinese-Canadian artist, stands at the forefront of pushing the boundaries of human-machine collaboration in the art realm.

Key Points: 
  • Sougwen Chung, a Chinese-Canadian artist, stands at the forefront of pushing the boundaries of human-machine collaboration in the art realm.
  • K11 MUSEA is a pioneering cultural retail landmark located on the Victoria Dockside harbourfront of Tsim Sha Tsui in Hong Kong.
  • In addition to the featured works at K11 MUSEA, Sougwen will also be launching a new body of work, titled 'GENESIS' at Hong Kong's prestigious Soho House.
  • Venue: 6F, K11 Art & Cultural Centre, K11 MUSEA, Tsim Sha Tsui, Hong Kong.

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Retrieved on: 
Friday, February 16, 2024
G-CSF, PD, CD34, TEL, HSC, Stem cell, Safety, Society, Pharmacokinetics, GENESIS, BioLineRx, Patient, Multiple myeloma, Transplant, Filgrastim, Risk, Dentistry

Phase 1 study results demonstrated an extended PD effect with complete receptor occupancy by motixafortide starting at a concentration of 3nM.

Key Points: 
  • Phase 1 study results demonstrated an extended PD effect with complete receptor occupancy by motixafortide starting at a concentration of 3nM.
  • In the GENESIS trial, post-hoc subgroup analyses based on baseline characteristics and risk factors for impaired HSC mobilization demonstrated a consistent benefit of motixafortide + G-CSF over placebo + G-CSF mobilization for all patients.
  • Poster Presentations at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the ASTCT and the CIBMTR.
  • Title: Motixafortide Enables Consistent, Robust Hematopoietic Stem Cell Collection (HSC) across Populations with Increased Impaired HSC Mobilization: A Sub-Group Analysis of the Genesis Study
    Presenter: Zachary D. Crees, MD, Washington University School of Medicine in St. Louis

TeleVox Expands Overseas to Support United States Military with Appointment and Referral Reminders

Retrieved on: 
Wednesday, January 10, 2024
Woman, Navy, GENESIS, Military Health System, Communication, MHS, SMS, Air force, Defense, Army

MOBILE, Ala., Jan. 10, 2024 (GLOBE NEWSWIRE) -- TeleVox , the industry-leading provider of omnichannel patient relationship management platforms, is proud to announce the expansion of its solutions to support the United States military overseas.

Key Points: 
  • MOBILE, Ala., Jan. 10, 2024 (GLOBE NEWSWIRE) -- TeleVox , the industry-leading provider of omnichannel patient relationship management platforms, is proud to announce the expansion of its solutions to support the United States military overseas.
  • The notifications include medical and dental appointment management, as well as referrals for Army, Navy, and Air Force service members and their families.
  • “At TeleVox, we take great pride in providing our innovative and reliable technology solutions to support the brave men and women who selflessly serve our country,” Krishnan said.
  • Serving the military community is at the core of our values, and we are dedicated to making a positive impact in their lives.”

Weber ‘Brings the Heat’ With Series of Industry-First, Intelligently Designed Innovations to Make Cooking Outdoors More Enjoyable and Delicious Than Ever

Retrieved on: 
Tuesday, January 9, 2024
Home Goods, Food Tech, Specialty, Consumer Electronics, Technology, Apps, Applications, Food, Beverage, Retail, CONNECT, Camping, Heart, GENESIS, Barbecue, Geography, Collection, Temperature, Cooking, Griddle, SLATE, Stainless steel, SPIRIT, Baking

"Our company's latest products are our most advanced and innovative yet," said Mike Jacobs, Chief Operating Officer of Weber.

Key Points: 
  • "Our company's latest products are our most advanced and innovative yet," said Mike Jacobs, Chief Operating Officer of Weber.
  • The all-new 2024 SUMMIT smart gas grill is the most technologically advanced, versatile, premium offering in the Company’s gas portfolio.
  • Weber designed it exclusively for outdoor cooks who seek a high-performing culinary showstopper for their outdoor space.
  • For the ultimate smart and easy-to-manage grilling experience, SUMMIT gas grill owners can also rely on the WEBER CONNECT App.

Keystone Dental Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, November 28, 2023
Nexus, Dental implant, GENESIS, FBC, Business analyst, Workflow, Patent, 3D, Annual, Meeting, Menachem Begin, Keystone, Algorithm, Dentistry

IRVINE, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings (“Keystone Dental” or the “Company”), a pioneer in dental implant technology, announced today financial results and provided a corporate update for the third quarter and nine months ended September 30, 2023.

Key Points: 
  • Q3 revenue increased 18.9% year-over-year to $16.8M, including $11.9M from the U.S.
    Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual General Meeting on Monday, December 18th, 2023
    IRVINE, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings (“Keystone Dental” or the “Company”), a pioneer in dental implant technology, announced today financial results and provided a corporate update for the third quarter and nine months ended September 30, 2023.
  • Sustained Revenue Growth – Total third quarter 2023 revenue increased 18.9% to $16.8 million compared to the same period in 2022, which was driven by increased sales of dental implants and Osteon product groups.
  • Revenue generated in the U.S. totaled $11.9 million in the third quarter of 2023 and $35.9 million for the nine months ended September 30, 2023.
  • In August 2023, Keystone Dental and Check-Cap announced entering into a definitive Business Combination Agreement (the "Business Combination Agreement") under which the stockholders of Keystone Dental will become the majority holders of the combined company.

Keystone Dental Announces Launch of the GENESIS ACTIVE™ Dental Implant System: Revolutionizing Dental Implantology

Retrieved on: 
Monday, November 13, 2023
Health, Abutment, Research, GENESIS, United, DGS, Dentistry, Bookbinding, Medical device, Dam

IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings (“Keystone Dental” or the “Company”), a pioneer in dental implant technology, announced today the commercial launch of GENESIS ACTIVE™ Implant System, a state-of-the-art surgical solution that is expected to transform how dental professionals approach implant placement and restoration.

Key Points: 
  • IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings (“Keystone Dental” or the “Company”), a pioneer in dental implant technology, announced today the commercial launch of GENESIS ACTIVE™ Implant System, a state-of-the-art surgical solution that is expected to transform how dental professionals approach implant placement and restoration.
  • “The GENESIS ACTIVE Implant System is a game-changing innovation that marks a new area in dental implantology.
  • With a solid commitment to meaningful innovation, patient care, and scientifically proven concepts, we aim to redefine the standard of implant procedures,” said Melker Nilsson, CEO of Keystone Dental.
  • “The GENESIS ACTIVE Dental Implant System brings together a robust portfolio of dental implant technologies into a single solution that is intended to empower dental professionals to deliver clinically proven implant treatment with greater efficiency.”
    The GENESIS ACTIVE Implant System is a comprehensive, innovative restorative portfolio of solutions that is backed by over a decade of research and development.

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Retrieved on: 
Monday, November 20, 2023
NDA, Pancreatic cancer, Safety, Research, NCCN, Sickle cell disease, ASH, Liver, Clinical trial, Patient, PRS, Natalizumab, FDA, Marketing, PDAC, G&A, Conference, Partnership, EST, Biomarker, Columbia University, Society, TEL, BioLineRx, GENESIS, Poster, TASE, AACR, Pharmaceutical industry, Rare-earth element, Cryptocurrency

- Management to host conference call today, November 20, at 10:00 a.m. EST -

Key Points: 
  • - Management to host conference call today, November 20, at 10:00 a.m. EST -
    TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2023, and provided corporate and portfolio updates.
  • "In addition, the company also closed its motixafortide licensing agreement covering the important Asia market.
  • The highly encouraging data triggered a change in the protocol, from a small, single-arm study to a much larger randomized study.
  • A dial-in replay of the call will be available until November 22, 2023; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

Scotiabank Announces 2023 Net-Zero Research Fund Winners

Retrieved on: 
Tuesday, November 7, 2023
Hydrogen, Carbon, Grenfell Campus, MRV, Bank, Water, Public policy, Seaweed, BOCP, PEACH, DAC, Sherbrooke, Coffee, Chief sustainability officer, Organization, RAE, Research, RAC, Communication, Senior, University of Alberta, Transport, Farmer, Soil, CO2, Memorial University of Newfoundland, GHG, University, GENESIS, CDR, Environmental science, Climate change, Renewable energy, Agriculture, Scotiabank

Scotiabank grants $1 million to research institutes across Canada, the US and Latin America exploring decarbonization opportunities

Key Points: 
  • Scotiabank grants $1 million to research institutes across Canada, the US and Latin America exploring decarbonization opportunities
    TORONTO, Nov. 7, 2023 /CNW/ - Today, Scotiabank announced the 10 winners of its global 2023 Net-Zero Research Fund.
  • The fund will provide $10 million in grants over 10 years to organizations conducting research and leading initiatives in support of the transition to a low-carbon economy.
  • The 2023 winners from Canada, the US and Latin America will collectively receive grants totalling $1 million to help advance and develop research focused on carbon emissions measurement, capture and reduction.
  • The next call-for-submissions for the Net-Zero Research Fund will be held in the spring of 2024.

BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

Retrieved on: 
Monday, September 11, 2023
Gene, Subliminal Sessions 6, Multiple myeloma, Survival, Cancer, Research, BioLineRx, Cellulitis, History, Doctor of Philosophy, EDT, Stem cell, Pain, Vomiting, TEL, Incidence, Injection site reaction, ASCT, MD, Collection, Patient, Transplant, Pathology, Hypokalemia, Erythema, Itch, Filgrastim, Physician, Washington University School of Medicine, G-CSF, Rare, B cell, FDA, Hypoxia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Society, Food, Pharmaceutical industry, Vaccine, GENESIS, Medicine

TEL AVIV, Israel, Sept. 11, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved APHEXDA™ (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA is administered by injection, for subcutaneous use.

Key Points: 
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9174951-biolinerx-fda-approval-a...
    Multiple myeloma is the second most-common hematologic malignancy.
  • Autologous stem cell transplantation (ASCT) is part of the standard of care treatment paradigm for multiple myeloma and delivers prolonged survival for patients with this cancer type.1 The success of ASCT depends on adequate mobilization of stem cells during the treatment process.
  • Part 1 was a single center, lead-in, open-label study involving 12 patients treated with motixafortide plus filgrastim designed to ascertain the dose.
  • In GENESIS, the safety was evaluated in 92 patients with multiple myeloma who received APHEXDA 1.25 mg/kg subcutaneously plus filgrastim, and 42 patients who received placebo plus filgrastim.

AMFRESH Group and EQT Future Successfully Complete 100% Acquisition of IFG and Merge with SNFL Group to Launch Global Breeding Powerhouse: BLOOM FRESH International

Retrieved on: 
Wednesday, August 16, 2023
Allen & Overy, Taste, International Fruit Genetics, Partnership, Citrus, Tropics, Genetics, Breeding, Fruit, PwC, Fountain Fresh International, EQT, Acquisition, GENESIS, Water, Growth, Dentons, Morrison & Foerster, Economics, BLOOM, Agriculture, Management, Earth

This momentous milestone has catalyzed the merger with AMFRESH’s SNFL Group, an industry leader in table grape genetics, paving the way for the birth of an extraordinary global breeding entity: BLOOM FRESH International.

Key Points: 
  • This momentous milestone has catalyzed the merger with AMFRESH’s SNFL Group, an industry leader in table grape genetics, paving the way for the birth of an extraordinary global breeding entity: BLOOM FRESH International.
  • Marking a historic milestone, AMFRESH Group, EQT Future and Paine Schwartz Partners successfully complete the acquisition of International Fruit Genetics, merging it into SNFL Group to establish BLOOM FRESH International as a consolidated breeding powerhouse.
  • Alvaro Muñoz, AMFRESH's Chief Executive Officer, exclaims, "Today signifies a pivotal moment, uniting two global breeding forces.
  • AMFRESH is the controlling shareholder of BLOOM, with significant minority investment from EQT Future and continued investment from Paine Schwartz Partners.